
浏览全部资源
扫码关注微信
南华大学 附属长沙市中心医院,药学院,长沙 410000
程艳,在读硕士,从事肿瘤药理学研究,E-mail:shiyihechengyan@163.com
高利臣,博士,副主任药师,硕士生导师,从事抗肿瘤药理研究,Tel:0731-85667812,E-mail:89206346@qq.com
收稿日期:2021-03-23,
网络出版日期:2021-05-08,
纸质出版日期:2021-07-05
移动端阅览
程艳,隆会芝,罗红宇等.基于网络药理学和细胞实验探究莲子心生物碱防治非小细胞肺癌的分子机制[J].中国实验方剂学杂志,2021,27(13):164-171.
CHENG Yan,LONG Hui-zhi,LUO Hong-yu,et al.Molecular Mechanism of Nelumbinis Plumula Alkaloids in Prevention and Treatment of Non-Small Cell Lung Cancer: an Analysis Based on Network Pharmacology and Cell Experiment[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(13):164-171.
程艳,隆会芝,罗红宇等.基于网络药理学和细胞实验探究莲子心生物碱防治非小细胞肺癌的分子机制[J].中国实验方剂学杂志,2021,27(13):164-171. DOI: 10.13422/j.cnki.syfjx.20210912.
CHENG Yan,LONG Hui-zhi,LUO Hong-yu,et al.Molecular Mechanism of Nelumbinis Plumula Alkaloids in Prevention and Treatment of Non-Small Cell Lung Cancer: an Analysis Based on Network Pharmacology and Cell Experiment[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(13):164-171. DOI: 10.13422/j.cnki.syfjx.20210912.
目的
2
基于网络药理学探究莲子心生物碱(NAPs)防治非小细胞肺癌(NSCLC)的潜在分子机制。
方法
2
通过搜索中药系统药理数据库及分析平台(TCMSP),中药分子机制的生物信息学分析工具(BATMAN-TCM)数据库获取NAPs主要活性成分,结合靶点预测平台Swiss Target Prediction预测分析其主要靶点。通过GeneCards,人类孟德尔遗传数据库(OMIM),DrugBank数据库获取NSCLC主要靶点。提交二者交集靶点至STRING平台构建蛋白质-蛋白质相互作用(PPI)网络,通过DAVID平台并对其进行基因本体(GO)和京都基因和基因百科全书(KEGG)分析。利用Cytoscape 3.7.1软件生成NAPs-交集靶点-通路”网络。此外,选择异莲心碱处理肺癌细胞A549,用倒置荧光显微镜观察细胞形态变化,细胞增殖与活性检测试剂盒-8(CCK-8)法检测异莲心碱对A549活力的影响,并用蛋白免疫印迹法(Western blot)验证预测靶点分子蛋白变化。
结果
2
NAPs中治疗NSCLC主要成分有莲明碱、莲心碱和异莲心碱(ISO)等;主要涉及通路包括磷脂酰肌醇3-激酶/蛋白激酶B(PI3K/AKT),Ras相关蛋白1(Rap1),受体酪氨酸激酶家族(ErbB)和缺氧诱导因子-1(HIF-1)通路,其功能主要为结合三磷酸腺苷(ATP)及调节蛋白激酶活性;主要靶点包括蛋白激酶B-1(AKT1),磷脂酰肌醇-3-激酶催化亚基α基因(PIK3CA),周期蛋白依赖激酶2(CDK2),丝裂原活化蛋白激酶-1(MAPK1),表皮生长因子受体(EGFR),三磷酸腺苷结合盒基因-1(ABCB1),雷帕霉素靶蛋白(mTOR),酪氨酸激酶(Src),Janus蛋白酪氨酸激酶(JAK1)和G1/S-特异性周期蛋白-D
1
(CCND1)等;体外细胞试验也证实,ISO能以浓度和时间依赖下调磷酸化蛋白激酶B(p-AKT)和磷酸化雷帕霉素靶蛋白(p-mTOR)的表达,抑制肺癌细胞A549生长。
结论
2
NAPs可以通过多成分、多靶点及多通路防治NSCLC,其最主要通过PI3K-AKT通路抑制非小细胞肺癌。
Objective
2
To explore the potential molecular mechanism of Nelumbinis Plumula alkaloids (NAPs) in the prevention and treatment of non-small cell lung cancer (NSCLC) based on network pharmacology and cell experiment.
Method
2
The main active components of NAPs were obtained by searching Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) and Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine (BATMAN-TCM), and their main targets were predicted and analyzed by employing Swiss Target Prediction. The main target genes of NSCLC were retrieved from GeneCards, Online Mendelian Inheritance in Man (OMIM) and DrugBank databases. The resulting common targets were imported into STRING platform for constructing the protein-protein interaction (PPI) network, followed by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis based on Database for Annotation, Visualization, and Integrated Discovery (DAVID). The NAPs-common target -pathway network was constructed by Cytoscape 3.7.1. After NSCLC cell line A549 was treated with isoliensinine, the cell morphology was observed under an inverted fluorescence microscope. The effect of isoliensinine on A549 vitality was detected by cell counting kit-8 (CCK-8) assay and the target protein changes were verified by Western blot.
Result
2
The main active components for NAPs against NSCLC were lysicamine, liensinine, and isoliensinine. The phosphatidylinositol-3-kinase-protein kinase B (PI3K-AKT), RAS-related protein 1 (Rap1), epidermal growth factor family of receptor tyrosine kinases (ErbBs), and hypoxia inducible factor-1 (HIF-1) pathways were mainly involved for binding adenosine triphosphate (ATP) and regulating protein kinase activity. The main targets included protein kinase B-1 (AKT1), alpha catalytic subunit of phosphoinositol-3-kinase (PIK3CA), cyclin-dependent kinase 2 (CDK2), mitogen-activated protein kinase-1 (MAPK1), epidermal growth factor receptor (EGFR), adenosine triphosphate-binding cassette B1 (ABCB1), mammalian target of rapamycin (mTOR), tyrosine kinase (Src), Janus kinase 1 (JAK1), and G1-phase-specific gene cyclin-D
1
(CCND1). The
in vitro
cell experiment also revealed that isoliensinine down-regulated the expression of phosphorylated AKT (p-AKT) and phosphorylated mTOR (p-mTOR) in a concentration- and time-dependent manner and inhibited the growth of A549 cells.
Conclusion
2
NAPs exert the preventive and therapeutic effects against NSCLC through multiple components, multiple targets, and multiple pathways, especially the PI3K-AKT pathway.
葛均波 , 徐永健 . 内科学 [M]. 8版 . 北京 : 人民卫生出版社 , 2014 : 75 .
BRAY F , FERLAY J , SOERJOMATARAM I , et al . Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2018 , 68 ( 6 ): 394 - 424 .
程伟 , 陈新梅 . 中药抗非小细胞肺癌作用机制研究进展 [J]. 中国实验方剂学杂志 , 2020 , 26 ( 24 ): 227 - 234 .
施继尧 , 王蒙 , 吴弢 . 莲子心的化学成分及生物活性研究进展 [J]. 中医药导报 , 2018 , 24 ( 21 ): 105 - 108 .
CHEN S X , LI J , WU J , et al . Plumula nelumbinis:a review of tradition-al uses,phytochemistry,pharmacology,pharmacokinetics and safety [J]. J Ethnopharmacol , 2021 , 266 : 113429 .
占秋晓 , 李丹丹 , 刘璐 , 等 . 基于网络药理学探究莲子心治疗高血压的分子机制 [J]. 中西医结合心脑血管病杂志 , 2020 , 18 ( 7 ): 1039 - 1045 .
蒋跃平 , 陈章义 , 莫芳 , 等 . 基于网络药理学的莲子心中生物碱类成分发挥传统安神功效的药理机制研究 [J]. 中国中药杂志 , 2019 , 44 ( 19 ): 4225 - 4233 .
PAUDEL K R , PANTH N . Phytochemical profile and biological activity of Nelumbo nucifera [J]. Evid Based Complement Alternat Med , 2015 , 2015 : 789124 .
张京梅 , 李鹏跃 , 王岚 , 等 . 莲子心总生物碱的提取分离及药效学初步研究 [J]. 中国实验方剂学杂志 , 2009 , 15 ( 6 ): 26 - 28 .
赵秀玲 , 党亚丽 . 莲子心化学成分及其提取、药理作用的研究进展 [J]. 食品科学 , 2018 , 39 ( 23 ): 329 - 336 .
LIN Z T , YANG R N , GUAN A , et al . Ultra-performance LC separation and quadrupole time-of-flight MS identification of major alkaloids in Plumula nelumbinis [J]. Phytochem Anal , 2014 , 25 ( 6 ): 485 - 494 .
但文超 , 何庆勇 , 曲艺 , 等 . 基于网络药理学的枳术丸调治血脂异常的分子机制研究 [J]. 世界科学技术—中医药现代化 , 2019 , 21 ( 11 ): 2396 - 2405 .
VELLA D , MARINI S , VITALI F , et al . MTGO:PPI network analysis via topological and functional module identification [J]. Sci Rep , 2018 , 8 ( 1 ): 929 - 940 .
田建辉 .“ 正虚伏毒”为肺癌发病的核心病机 [J]. 上海中医药杂志 , 2016 , 50 ( 12 ): 10 - 14 .
LIAO C H , LIN J Y . Lotus ( Nelumbo nucifera Gaertn) plumule polysaccharide protects the spleen and liver from spontaneous inflammation in non-obese diabetic mice by modulating pro-/anti-inflammatory cytokine gene expression [J]. Food Chem , 2011 , 129 ( 2 ): 245 - 252 .
史霄燕 , 胡文淑 . 甲基莲心碱对高脂血症患者及健康成人血小板聚集的影响 [J]. 中国药理学通报 , 1998 ( 3 ): 237 - 239 .
李希珍 . 莲子心化学成分及生物活性的研究 [D]. 长春 : 吉林大学 , 2016 .
ZHAO X , SHEN J , CHANG K J , et al . Comparative analysis of antioxidant activity and functional components of the ethanol extract of lotus ( Nelumbo nucifera ) from various growing regions [J]. J Agric Food Chem , 2014 , 62 ( 26 ): 6227 - 6235 .
XIAO J H , ZHANG J H , CHEN H L , et al . Inhibitory effects of isoliensinine on bleomycin-induced pulmonary fibrosis in mice [J]. Planta Med , 2005 , 71 ( 3 ): 225 - 230 .
邓碧 . 莲子心提取物对糖尿病大鼠肾脏保护作用及其机制研究 [D]. 成都 : 成都医学院 , 2015 .
WANG gang , WANG ping , YAN Xiaojun , et al . Neferine hinders choriocarcinoma cell proliferation,migration and invasion through repression of long noncoding RNA-CHRF [J]. Artif Cells Nanomed Biotechnol , 2019 , 47 ( 1 ): 4089 - 4096 .
ZHOU J , LI G , ZHENG Y , et al . A novel autophagy/mitophagy inhibitor liensinine sensitizes breast cancer cells to chemotherapy through DNM1L-mediated mitochondrial fission [J]. Autophagy , 2015 , 11 ( 8 ): 1259 - 1279 .
SHU G , ZHANG L , JIANG S , et al . Isoliensinine induces dephosphorylation of NF- k B p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells:roles of impairing PP2A/I2PP2A interaction [J]. Oncotarget , 2016 , 7 ( 26 ): 40285 - 40296 .
LIU X , WANG P , ZHANG C , et al . Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer [J]. Oncotarget , 2017 , 8 ( 30 ): 50209 - 50220 .
TAN , A C . Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC) [J]. Thorac Cancer , 2020 , 11 ( 3 ): 511 - 518 .
TADESSE S , ANSHABO A T , PORTMAN N , et al . Targeting CDK2 in cancer: challenges and opportunities for therapy [J]. Drug Discov Today , 2020 , 25 ( 2 ): 406 - 413 .
ZHANG Z Y , GAO X H , MA M Y , et al . CircRNA 101237 promotes NSCLC progression via the miRNA 490-3p/MAPK1 axis [J]. Sci Rep , 2020 , 10 ( 1 ): 9024 .
0
浏览量
18
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621